third quarter 2026
Filed Nov 5, 2026Dogwood Therapeutics Announces Third Quarter 2026 Financial Results
Third-quarter net loss and research and development expense declined sharply from the prior-year period, while the company reported $4.9 million of cash on hand and a $5 million private placement that it says provides runway through the first quarter of 2027. The investment case remains centered on pending November 2026 top-line Phase 2b CINP results for Halneuron, with limited licensing revenue and no reported operating cash flow.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Licensing revenue, three months ended September 30GAAP | $100,000 | – | – |
| CVR expense, three months ended September 30GAAP | $88,104 | – | – |
| Gross profit, three months ended September 30GAAP | $11,896 | – | – |
| Research and development expenses, three months ended September 30GAAP | $3,352,977 | – | $11.2 million decrease year over year |
| General and administrative expenses, three months ended September 30GAAP | $1,576,219 | – | $0.3 million increase year over year |
| IPR&D impairment, three months ended September 30GAAP | $— | – | – |
| Total operating expenses, three months ended September 30GAAP | $4,929,196 | – | – |
| Loss from operations, three months ended September 30GAAP | $(4,917,300) | – | – |
| Sublease income, three months ended September 30GAAP | $27,241 | – | – |
| Loss on debt conversion with related party, three months ended September 30GAAP | $— | – | – |
| Interest income, net, three months ended September 30GAAP | $42,035 | – | – |
| Exchange loss, net, three months ended September 30GAAP | $(35,757) | – | – |
| Total other income (expense), net, three months ended September 30GAAP | $33,519 | – | – |
| Loss before income taxes, three months ended September 30GAAP | $(4,883,781) | – | – |
| Deferred income tax benefit (expense), three months ended September 30GAAP | $839 | – | – |
| Net loss, three months ended September 30GAAP | $(4,882,942) | – | – |
| Net loss attributable to common stockholders, three months ended September 30GAAP | $(4,882,942) | – | – |
| Net loss per share of common stock, basic and diluted, three months ended September 30GAAP | $(0.14) | – | – |
| Weighted average shares outstanding, basic and diluted, three months ended September 30other | 34,129,553 | – | – |
| Licensing revenue, nine months ended September 30GAAP | $100,000 | – | – |
| CVR expense, nine months ended September 30GAAP | $88,104 | – | – |
| Gross profit, nine months ended September 30GAAP | $11,896 | – | – |
| Research and development expenses, nine months ended September 30GAAP | $9,269,275 | – | – |
| General and administrative expenses, nine months ended September 30GAAP | $5,608,915 | – | – |
| IPR&D impairment, nine months ended September 30GAAP | $9,190,897 | – | – |
| Total operating expenses, nine months ended September 30GAAP | $24,069,087 | – | – |
| Loss from operations, nine months ended September 30GAAP | $(24,057,191) | – | – |
| Sublease income, nine months ended September 30GAAP | $64,138 | – | – |
| Loss on debt conversion with related party, nine months ended September 30GAAP | $— | – | – |
| Interest income, net, nine months ended September 30GAAP | $185,734 | – | – |
| Exchange loss, net, nine months ended September 30GAAP | $(72,186) | – | – |
| Total other income (expense), net, nine months ended September 30GAAP | $177,686 | – | – |
| Loss before income taxes, nine months ended September 30GAAP | $(23,879,505) | – | – |
| Deferred income tax benefit (expense), nine months ended September 30GAAP | $2,480,340 | – | – |
| Net loss, nine months ended September 30GAAP | $(21,399,165) | – | – |
| Accrual of paid-in-kind dividends on Series A non-voting convertible preferred stock, nine months ended September 30GAAP | $— | – | – |
| Net loss attributable to common stockholders, nine months ended September 30GAAP | $(21,399,165) | – | – |
| Net loss per share of common stock, basic and diluted, nine months ended September 30GAAP | $(0.63) | – | – |
| Weighted average shares outstanding, basic and diluted, nine months ended September 30other | 33,936,760 | – | – |
November 2026, early 2027 and first quarter of 2027 outlook
- NoteTop-line results from the recently completed Phase 2b CINP study are expected to be announced in November 2026.
- NoteThe Phase 2b long-term extension study is expected to be completed in early 2027.
- NoteCash on hand of $4.9 million along with the private placement of $5 million provides operational runway through the first quarter of 2027.
What drove it
- The company recognized $0.1 million in licensing revenue for its first payment under the PRIDCor License Agreement.
- The company recognized cost of goods sold of $0.1 million related to the corresponding payment to CVR Holders under the CVR Agreement.
- The research and development expense decrease primarily reflected a $12.0 million decrease in acquired IPR&D expenses related to the Serpin Licensing Agreement that took place in the third quarter of 2025.
- The research and development change was partly offset by a $0.5 million increase in Halneuron Phase 2b CINP study costs, a $0.2 million increase in drug development and manufacturing costs, and a $0.1 million increase in salaries and related personnel costs.
- General and administrative expense increased primarily due to a $0.4 million increase in salaries and related personnel costs, partly offset by a $0.1 million decrease in legal and accounting fees.
Concerns
- The company reported a net loss attributable to common stockholders of $4.9 million for the third quarter of 2026 and $21.4 million for the nine months ended September 30, 2026.
- Cash and cash equivalents were $4,948,266 as of September 30, 2026, and the company states that cash on hand plus the $5 million private placement provides runway only through the first quarter of 2027.
- Third-quarter licensing revenue was $100,000 and gross profit was $11,896.
- The company recorded $9,190,897 of IPR&D impairment for the nine months ended September 30, 2026.
What to watch
- Top-line results from the completed 239-patient Halneuron Phase 2b CINP study, expected in November 2026.
- Completion of the Phase 2b long-term extension study, which has fully enrolled 95 patients and is expected to be completed in early 2027.
- Use of proceeds from the $5 million private placement for Phase 3 preparatory activities, working capital and general corporate purposes.
- The company's operating runway through the first quarter of 2027.
Balance sheet and cash flow
- Cash and cash equivalents as of September 30, 2026: $4,948,266; December 31, 2025: $6,524,744.
- Total assets as of September 30, 2026: $75,608,219; December 31, 2025: $90,171,237.
- Total liabilities as of September 30, 2026: $11,475,000; December 31, 2025: $15,274,370.
- Total stockholders’ equity as of September 30, 2026: $64,133,219; December 31, 2025: $74,896,867.
- Closed a $5 million private placement with Sealbond Limited to advance Phase 3 preparatory activities for Halneuron and for working capital and general corporate purposes.
Analysis
Dogwood reported limited third-quarter commercial-related revenue, with licensing revenue of $100,000 and CVR expense of $88,104, resulting in gross profit of $11,896. The company remains a development-stage biopharmaceutical company, and the quarter's central operating event was completion of the Halneuron Phase 2b CINP study, which enrolled 239 patients. Top-line results are expected in November 2026.
Third-quarter research and development expense was $3,352,977, compared with $14,521,342 in the third quarter of 2025. Management attributed the $11.2 million decrease primarily to a $12.0 million decline in acquired IPR&D expense related to the Serpin Licensing Agreement in the prior-year quarter. Current development spending moved higher in several areas, including $0.5 million of Halneuron Phase 2b CINP study costs, $0.2 million of drug development and manufacturing costs, and $0.1 million of salaries and related personnel costs.
General and administrative expense increased to $1,576,219 from $1,287,783, driven primarily by a $0.4 million increase in salaries and related personnel costs, partly offset by a $0.1 million decrease in legal and accounting fees. Net loss attributable to common stockholders was $(4,882,942), or $(0.14) basic and diluted net loss per share, compared with $(15,744,616), or $(8.20) basic and diluted net loss per share. For the nine-month period, the company recorded an IPR&D impairment of $9,190,897 and net loss attributable to common stockholders of $(21,399,165).
Liquidity is a key focus. Cash and cash equivalents were $4,948,266 as of September 30, 2026. Dogwood also closed a $5 million private placement with Sealbond Limited, which it said will support Phase 3 preparatory activities for Halneuron, working capital and general corporate purposes. Management stated that cash on hand together with the private placement provides operational runway through the first quarter of 2027.
Clinical execution and the upcoming readout dominate the near-term outlook. The company has fully enrolled 95 patients in its Phase 2b long-term extension study assessing pain reduction over three months of Halneuron treatment, with completion expected in early 2027. The November 2026 Phase 2b CINP top-line results will be the principal reported catalyst, followed by the company's ability to advance Phase 3 preparatory activities within its stated runway.
Management, verbatim
Despite the massive unmet medical need associated with significant pain from ‘off-target’ chemotherapy-related nerve damage, there are no FDA approved medicines to treat CINP. Halneuron ® has demonstrated statistically and/or clinically significant and durable pain reduction in cancer and CINP clinical trials to date. With results from the recently completed Phase 2b CINP study to be reported in November, we believe that if successful, Halneuron ® could represent the first new therapeutic agent for millions of CINP patients in the US and tens of millions of CINP patients across the globe.
Greg Duncan, Chief Executive Officer of Dogwood Therapeutics
Not in the filing
stated, not guessed- Gross margin was not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Debt balance was not reported.
- Capital returns, including share repurchases and cash dividends, were not reported.
- Formal financial guidance for revenue, gross margin, operating expenses, or tax rate was not reported.
- Sequential, prior-quarter comparisons were not reported.
- Non-GAAP financial measures were not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.